Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:appointed_by |
oral capsule
|
| gptkbp:approves |
gptkb:FDA
2001-01-31 |
| gptkbp:brand |
gptkb:Avodart
|
| gptkbp:class |
5-alpha-reductase inhibitor
|
| gptkbp:clinical_trial |
Phase III
symptomatic relief 60% to 90% improving urinary flow preventing acute urinary retention reducing need for surgery reducing prostate size |
| gptkbp:contraindication |
blood donation
pregnancy hypersensitivity to dutasteride |
| gptkbp:dosage_form |
gptkb:beer
|
| gptkbp:duration |
long-term
|
| gptkbp:excretion |
urine
feces |
| gptkbp:formulation |
soft gelatin capsule
|
| https://www.w3.org/2000/01/rdf-schema#label |
Avodart
|
| gptkbp:indication |
male pattern baldness
prostate enlargement |
| gptkbp:ingredients |
dutasteride
|
| gptkbp:interacts_with |
gptkb:warfarin
other 5-alpha-reductase inhibitors |
| gptkbp:invention |
2015-09-30
|
| gptkbp:is_atype_of |
G04 C B02
|
| gptkbp:is_monitored_by |
liver function tests
PSA levels |
| gptkbp:is_used_for |
benign prostatic hyperplasia
|
| gptkbp:lifespan |
5 weeks
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:marketed_as |
gptkb:United_Kingdom
gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:metabolism |
liver
|
| gptkbp:population |
adult men
|
| gptkbp:requires |
available online
|
| gptkbp:scholarships |
take with or without food
not to be handled by women |
| gptkbp:side_effect |
dizziness
fatigue headache nausea allergic reactions rash breast tenderness decreased libido erectile dysfunction liver injury |
| gptkbp:social_structure |
C27 H30 F6 N2 O2 S
|
| gptkbp:storage |
room temperature
|
| gptkbp:bfsParent |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:bfsLayer |
3
|